Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 30, 2025Wiadomości Lekarskie

Retinal glial activation in diabetic retinopathy: therapeutic impact of multikinase inhibition with sorafenib

View Full Paper
Ask AI
Bookmark
Share

Authors

KUK.O. UsenkoСЗС. В. ЗяблицевDYDanylo I. Yevstifeiev

Discussion

Loading...

Member takes

Overview

Experimental analysis shows sorafenib reduces glial activation and preserves retinal structure in rats with diabetic retinopathy, suggesting its therapeutic potential.

Key Points

  • Untreated diabetic rats showed severe retinal oedema and increased microglial activation due to gliosis, indicating advanced damage.
  • Co-treatment with sorafenib significantly reduced glial marker expression compared to insulin monotherapy, preserving retinal structure.
  • Histological analysis using H&E staining and Western blotting assessed glial activation and neuroinflammatory changes in retinal samples.
  • Targeted multikinase inhibition may emerge as a novel strategy for managing early diabetic retinopathy-related changes.

Cite This Study

Usenko et al. (2025) studied this question.

synapsesocial.com/papers/68af5d63ad7bf08b1eae0994https://doi.org/10.36740/wlek/208991
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1REACTIVE RETINAL GLIOSIS IN EXPERIMENTAL DIABETIC RETINOPATHY AND THE EFFECT OF INHIBITION OF CELLULAR PROTEIN KINASES2025
  2. 2Retinal plasminogen and plasmin content in experimental diabetic retinopathy and the effect of pharmacological blockade of cellular protein kinases2025
  3. 3Neurodegenerative and Glial Physiology in Diabetic Retinopathy: Dissociated Effects of Forskolin on Neuronal Survival and Glial Activation2026
  4. 4Selective therapeutic efficacy of tyrosine kinase inhibitor sorafenib on the restoration of methylglyoxal-induced peritoneal fibrosis2024 · 1 citations
  5. 5Sodium‐Glucose Co‐Transporter‐2 Inhibitor Empagliflozin Attenuates Sorafenib‐Induced Myocardial Inflammation and Toxicity2024 · 9 citations